Article

Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

Banner Alzheimer's Institute and Banner Good Samaritan PET Center, Phoenix, AZ, USA.
NeuroImage (Impact Factor: 6.36). 06/2009; 45(4):1107-16. DOI: 10.1016/j.neuroimage.2008.12.072
Source: PubMed

ABSTRACT In mostly small single-center studies, Alzheimer's disease (AD) is associated with characteristic and progressive reductions in fluorodeoxyglucose positron emission tomography (PET) measurements of the regional cerebral metabolic rate for glucose (CMRgl). The AD Neuroimaging Initiative (ADNI) is acquiring FDG PET, volumetric magnetic resonance imaging, and other biomarker measurements in a large longitudinal multi-center study of initially mildly affected probable AD (pAD) patients, amnestic mild cognitive impairment (aMCI) patients, who are at increased AD risk, and cognitively normal controls (NC), and we are responsible for analyzing the PET images using statistical parametric mapping (SPM). Here we compare baseline CMRgl measurements from 74 pAD patients and 142 aMCI patients to those from 82 NC, we correlate CMRgl with categorical and continuous measures of clinical disease severity, and we compare apolipoprotein E (APOE) varepsilon4 carriers to non-carriers in each of these subject groups. In comparison with NC, the pAD and aMCI groups each had significantly lower CMRgl bilaterally in posterior cingulate, precuneus, parietotemporal and frontal cortex. Similar reductions were observed when categories of disease severity or lower Mini-Mental State Exam (MMSE) scores were correlated with lower CMRgl. However, when analyses were restricted to the pAD patients, lower MMSE scores were significantly correlated with lower left frontal and temporal CMRgl. These findings from a large, multi-site study support previous single-site findings, supports the characteristic pattern of baseline CMRgl reductions in AD and aMCI patients, as well as preferential anterior CMRgl reductions after the onset of AD dementia.

Download full-text

Full-text

Available from: Kewei Chen, Aug 23, 2015
0 Followers
 · 
123 Views
  • Source
    • "One such extensively used neuroimaging technique is 18 F- Fluorodeoxyglucose positron emission tomography (FDG-PET) imaging, which can be used to evaluate the cerebral metabolic rate of glucose (CMRgl). Numerous FDG- PET studies (Nestor et al. 2003; Mosconi et al. 2005, 2008; Langbaum et al. 2009) have demonstrated significant reductions of CMRgl in brain regions in patients with AD and its prodromal stage mild cognitive impairment (MCI), compared with normal control (NC) subjects. These reduction could be used for the early detection of AD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Traditional voxel-level multiple testing procedures in neuroimaging, mostly p-value based, often ignore the spatial correlations among neighboring voxels and thus suffer from substantial loss of power. We extend the local-significance-index based procedure originally developed for the hidden Markov chain models, which aims to minimize the false nondiscovery rate subject to a constraint on the false discovery rate, to three-dimensional neuroimaging data using a hidden Markov random field model. A generalized expectation-maximization algorithm for maximizing the penalized likelihood is proposed for estimating the model parameters. Extensive simulations show that the proposed approach is more powerful than conventional false discovery rate procedures. We apply the method to the comparison between mild cognitive impairment, a disease status with increased risk of developing Alzheimer's or another dementia, and normal controls in the FDG-PET imaging study of the Alzheimer's Disease Neuroimaging Initiative. © 2015, The International Biometric Society.
    Biometrics 04/2014; DOI:10.1111/biom.12329 · 1.52 Impact Factor
  • Source
    • "a - men , thalamus , and gyrus rectus ( Tables 2 and 3 ) . Relative to FDG , 11 C - AcAc uptake was less influenced by age in the caudate , leading to proportionally higher AI in the caudate of young adults ( Fig . 5 ) . Interestingly , the caudate appears to be relatively spared from synaptic loss and resulting symptoms in Alzheimer ' s disease ( Langbaum et al . , 2009 ; Yuan et al . , 2010 ) . There were no sex differences in brain glucose or AcAc uptake in the elderly but , as previously reported ( Andreason et al . , 1994 ) , young women had 27% higher CMRg in the posterior cingulate when compared with young men . Hence , not only is lower brain glucose uptake in those aged >70 years clearly a regio"
    [Show abstract] [Hide abstract]
    ABSTRACT: The extent to which the age-related decline in regional brain glucose uptake also applies to other important brain fuels is presently unknown. Ketones are the brain's major alternative fuel to glucose, so we developed a dual tracer positron emission tomography protocol to quantify and compare regional cerebral metabolic rates for glucose and the ketone, acetoacetate. Twenty healthy young adults (mean age, 26 years) and 24 healthy older adults (mean age, 74 years) were studied. In comparison with younger adults, older adults had 8 ± 6% (mean ± SD) lower cerebral metabolic rates for glucose in gray matter as a whole (p = 0.035), specifically in several frontal, temporal, and subcortical regions, as well as in the cingulate and insula (p ≤ 0.01, false discovery rate correction). The effect of age on cerebral metabolic rates for acetoacetate in gray matter did not reach significance (p = 0.11). Rate constants (min(-1)) of glucose (Kg) and acetoacetate (Ka) were significantly lower (-11 ± 6%; [p = 0.005], and -19 ± 5%; [p = 0.006], respectively) in older adults compared with younger adults. There were differential effects of age on Kg and Ka as seen by significant interaction effects in the caudate (p = 0.030) and post-central gyrus (p = 0.023). The acetoacetate index, which expresses the scaled residuals of the voxel-wise linear regression of glucose on ketone uptake, identifies regions taking up higher or lower amounts of acetoacetate relative to glucose. The acetoacetate index was higher in the caudate of young adults when compared with older adults (p ≤ 0.05 false discovery rate correction). This study provides new information about glucose and ketone metabolism in the human brain and a comparison of the extent to which their regional use changes during normal aging.
    Neurobiology of aging 12/2013; 35(6). DOI:10.1016/j.neurobiolaging.2013.11.027 · 4.85 Impact Factor
  • Source
    • "The effect of APOE genotype on amyloid deposition has been shown previously, including in middle-aged and older cognitively healthy adults, as well as patients with L-MCI and AD (Drzezga et al., 2009; Shaw et al., 2009; Morris et al., 2010; Fleisher et al., 2011; Tosun et al., 2011). Biochemically, APOE genotype has "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Our goal was to evaluate the association of APOE with amyloid deposition, cerebrospinal fluid levels (CSF) of Aβ, tau, and p-tau, brain atrophy, cognition and cognitive complaints in E-MCI patients and cognitively healthy older adults (HC) in the ADNI-2 cohort. Methods: Two-hundred and nine E-MCI and 123 HC participants from the ADNI-2 cohort were included. We evaluated the impact of diagnostic status (E-MCI vs. HC) and APOE ε4 status (ε4 positive vs. ε4 negative) on cortical amyloid deposition (AV-45/Florbetapir SUVR PET scans), brain atrophy (structural MRI scans processed using voxel-based morphometry and Freesurfer version 5.1), CSF levels of Aβ, tau, and p-tau, and cognitive performance and complaints. Results: E-MCI participants showed significantly impaired cognition, higher levels of cognitive complaints, greater levels of tau and p-tau, and subcortical and cortical atrophy relative to HC participants (p < 0.05). Cortical amyloid deposition and CSF levels of Aβ were significantly associated with APOE ε4 status but not E-MCI diagnosis, with ε4 positive participants showing more amyloid deposition and lower levels of CSF Aβ than ε4 negative participants. Other effects of APOE ε4 status on cognition and CSF tau levels were also observed. Conclusions: APOE ε4 status is associated with amyloid accumulation and lower CSF Aβ, as well as increased CSF tau levels in early prodromal stages of AD (E-MCI) and HC. Alternatively, neurodegeneration, cognitive impairment, and increased complaints are primarily associated with a diagnosis of E-MCI. These findings underscore the importance of considering APOE genotype when evaluating biomarkers in early stages of disease.
    Frontiers in Aging Neuroscience 04/2013; 5:11. DOI:10.3389/fnagi.2013.00011 · 2.84 Impact Factor
Show more